

Special Issue

IgA, IgG and Cell-Mediated Immunity: A Comprehensive Understanding of Effective Respiratory Syncytial Virus (RSV) Vaccines

Message from the Guest Editor

Considering the complexity of RSV vaccination targets, which include infants, pregnant women and the elderly, we think it is time to summarize the experiences on the development of RSV vaccines based on non-inactivated technologies, in particular, those which can avoid immunopathology in infants, and those which may induce a high rate of protection and long-lasting efficacy in the elderly. In this Special Issue, contributions in the form of original research or reviews, including, but not limited to, the following topics are welcome: (i) basic research on RSV invasion and immunopathology; (ii) vaccine immunization strategies; (iii) vaccine antigen prefusion protein design; (iv) adjuvant effects to elevate vaccine efficacy and to lower the risk of immunopathology; and (v) strategies to avoid antibody decline and prolong vaccine efficacy.

Guest Editor

Dr. Cunbao Liu

Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China

Deadline for manuscript submissions

closed (30 September 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/138600

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).